On 15 February 2022, the Board of Directors of Duopharma Biotech declared a second interim dividend of 1.8 sen per ordinary share in Duopharma Biotech in respect of the financial year ended 31 December 2021. The second interim dividend is not taxable in the hands of the receiving shareholders.
The Board of Directors has resolved that the Dividend Reinvestment Plan (“DRP”), which was approved at the Company’s Extraordinary General Meeting held on 31 May 2018 and which provides the shareholders of the Company with the option to elect to reinvest their dividend in new Duopharma Biotech Shares, would apply to the second interim dividend.
The second interim dividend will be paid no later than 3 months from the date of declaration pursuant to Paragraph 8.26 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.
On 24 March 2022, Mercury Securities Sdn. Bhd, on behalf of the Board of Directors of Duopharma Biotech, announced that the issue price of the new ordinary shares in Duopharma Biotech (“Duopharma Shares”) to be issued pursuant to the DRP has been fixed (“Price Fixing Date”) at RM1.29 per new Duopharma Share.
The issue price is computed based on the 5-day volume weighted average market price of Duopharma Shares (“VWAMP”) up to 23 March 2022, being the last trading day prior to the Price Fixing Date of RM1.45 after adjusting for the following:
The entitlement date for the second interim dividend and DRP has been fixed on 15 April 2022. The payment date for the second interim dividend has been fixed on 13 May 2022.
On 28 March 2022, Mercury Securities Sdn. Bhd, on behalf of the Board of Directors of Duopharma Biotech, announced that the DRP will provide Shareholders with an option to elect to reinvest their entire electable portion or part of their electable portion into new Duopharma Shares, in lieu of receiving cash.